Details for Patent: 10,179,140
✉ Email this page to a colleague
Which drugs does patent 10,179,140 protect, and when does it expire?
Patent 10,179,140 protects DROSPIRENONE and SLYND and is included in two NDAs.
This patent has sixty-five patent family members in twenty-nine countries.
Summary for Patent: 10,179,140
| Title: | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| Abstract: | A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m.sup.2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration. |
| Inventor(s): | Perrin; Philippe (Paris, FR), Drouin; Dominique (Verrieres, FR), Boyer-Joubert; Cecile (Fontenay aux Roses, FR) |
| Assignee: | Laboratorios Leon Farma SA (Leon, ES) |
| Application Number: | 15/433,427 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,179,140 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 10,179,140
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | DROSPIRENONE | drospirenone | TABLET, CHEWABLE;ORAL | 216285-001 | Jun 29, 2022 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE | ⤷ Sign Up | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,179,140
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2588114 | ⤷ Sign Up | CA 2020 00023 | Denmark | ⤷ Sign Up |
| European Patent Office | 2588114 | ⤷ Sign Up | 2020C/518 | Belgium | ⤷ Sign Up |
| European Patent Office | 2588114 | ⤷ Sign Up | 19/2020 | Austria | ⤷ Sign Up |
| European Patent Office | 2588114 | ⤷ Sign Up | C202030026 | Spain | ⤷ Sign Up |
| European Patent Office | 2588114 | ⤷ Sign Up | 301123 | Netherlands | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
